Polytherics Ltd., of London, said its Thiobridge antibody drug conjugate (ADC) collaboration with Macrogenics Inc., of Rockville, Md., has been extended following the successful outcome of a research program undertaken in 2013 in which Thiobridge was used to conjugate a cytotoxic payload to a range of DART antibodies.